Overall ? The mission of the San Diego Center for AIDS Research (SD CFAR) is to find a cure for HIV for those already infected, and to prevent HIV transmission to those not infected. Our Center?s research priorities are aligned with the NIH Office of AID Research priorities and include: optimizing HIV care, alleviating HIV health disparities and advancing scientific discovery for HIV cure and vaccine efforts.
The specific aims of the SD CFAR are to: 1. Foster innovative HIV research by providing the foundation and framework for highly productive collaborations across disciplines, investigators, member institutions, and the HIV community. 2. Capitalize on our community engagement and international expertise to develop sustainable research programs locally and in targeted low and middle income countries highly impacted by HIV. 3. Provide Training, Inspiration, Mentoring, and Expert guidance (TIME) to local and international investigators across career stages. 4. Thoughtfully plan our Center?s growth and flexibility to adapt to an ever evolving research environment. Structure: The SD CFAR is multi-institutional, with members at La Jolla Institute of Allergy and Immunology (LJI), Sanford Burnham Prebys Medical Discovery Institute (SBP), The Scripps Research Institute (TSRI), and University of California San Diego (UCSD). The Center is co-directed by members of our Operations Team including Drs. Davey Smith (contact PI), Douglas Richman, Robert Schooley, and Bruce Torbett. Our CFAR is comprised of ten Cores and one Scientific Working Group. One of these Cores, the Disparities Core, is completely funded by the California HIV Research Program, but remains ingrained as a standalone Core in our Center. We continue to be guided by our External Advisory and Executive Committees, as well as our Co- Directors, Core Directors, Scientific Working Groups and our membership. Progress: Since our renewal in 2012, these efforts have yielded a productive, enthusiastic and growing group of investigators. As the synergy among our investigators and member institutions increases, we have identified the need to expand our infrastructure to address new opportunities. This success has culminated in our move from a Tier 2 to Tier 3 CFAR.
Overall - The SD CFAR supports basic, clinical, behavioral and translational research programs across our member institutions. These activities add considerable value to NIH funded HIV research. In addition to our active, productive and groundbreaking research, we have a remarkable program for fostering the development of emerging investigators, including scientists new to HIV research.
|Chaillon, Antoine; Gianella, Sara; Lada, Steven M et al. (2018) Size, Composition, and Evolution of HIV DNA Populations during Early Antiretroviral Therapy and Intensification with Maraviroc. J Virol 92:|
|Bengtson, Angela M; Pence, Brian W; Eaton, Ellen F et al. (2018) Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. Antivir Ther 23:363-372|
|Dubé, Karine; Gianella, Sara; Concha-Garcia, Susan et al. (2018) Ethical considerations for HIV cure-related research at the end of life. BMC Med Ethics 19:83|
|Letendre, Scott; Bharti, Ajay; Perez-Valero, Ignacio et al. (2018) Higher Anti-Cytomegalovirus Immunoglobulin G Concentrations Are Associated With Worse Neurocognitive Performance During Suppressive Antiretroviral Therapy. Clin Infect Dis 67:770-777|
|Basova, Liana; Najera, Julia A; Bortell, Nikki et al. (2018) Dopamine and its receptors play a role in the modulation of CCR5 expression in innate immune cells following exposure to Methamphetamine: Implications to HIV infection. PLoS One 13:e0199861|
|Mittal, María Luisa; Bazzi, Angela Robertson; Rangel, María Gudelia et al. (2018) 'He's not my pimp': toward an understanding of intimate male partner involvement in female sex work at the Mexico-US border. Cult Health Sex 20:961-975|
|de Almeida, Sérgio Monteiro; Ribeiro, Clea E; Rotta, Indianara et al. (2018) Biomarkers of neuronal injury and amyloid metabolism in the cerebrospinal fluid of patients infected with HIV-1 subtypes B and C. J Neurovirol 24:28-40|
|Martin, Thomas C S; Rauch, Andri; Salazar-Vizcaya, Luisa et al. (2018) Understanding and Addressing Hepatitis C Virus Reinfection Among Men Who Have Sex with Men. Infect Dis Clin North Am 32:395-405|
|Eren, Kemal; Murrell, Ben (2018) RIFRAF: a frame-resolving consensus algorithm. Bioinformatics 34:3817-3824|
|Stecher, M; Chaillon, A; Eis-Hübinger, A M et al. (2018) Pretreatment human immunodeficiency virus type 1 (HIV-1) drug resistance in transmission clusters of the Cologne-Bonn region, Germany. Clin Microbiol Infect :|
Showing the most recent 10 out of 921 publications